In brief
As antibiotic resistance escalates globally, particularly in India where it deeply impacts newborns and critically ill patients, promising homegrown antibiotics emerge as potential lifesavers. Enmetazobactam, the first Indian-invented antibiotic approved by the FDA, could revolutionize treatment. Alongside this, Mumbai's Wockhardt is set to launch Zaynich, a novel antibiotic displaying notable effectiveness against severe infections. However, experts stress that responsible usage and improved practices in antibiotic prescriptions are vital in curbing the growing threat of superbugs.
Drug-resistant infections are a growing concern, especially in critical care settings. Antibiotics, once reliable for their roles in treatment, are now met with a formidable opponent: bacteria. These pathogens adapt at an alarming rate, making the drugs designed to eliminate them less effective. Based on research published in The Lancet, antibiotic-resistant "superbugs" were responsible for approximately 1.14 million deaths worldwide by 2021, with India, unfortunately, among the nations battling this urgent public health crisis. In 2019, antimicrobial resistance alone led to around 300,000 fatalities in the South Asian nation, claiming the lives of an estimated 60,000 newborns annually.However, several promising locally-developed drugs represent a beacon of hope in this ongoing struggle. Enmetazobactam, which originated from Chennai's Orchid Pharma, stands out as the first antimicrobial conceived in India to gain approval from the US Food and Drug Administration (FDA). It tackles severe infections such as urinary tract infections (UTIs) and pneumonia by addressing the bacteria's defense mechanisms, rather than attacking the bacteria directly. This innovative approach allows it to neutralize the enzymes that bacteria produce to resist antibiotics, preserving the efficacy of critical last-resort treatments like carbapenems.Clinical trials spanning 19 countries have tested Enmetazobactam on over 1,000 patients, demonstrating its potency against evolved bacterial strains. As highlighted by Dr. Maneesh Paul, the lead co-inventor, it specifically caters to those in critical conditions through intravenous infusion, ensuring hospitals manage its use carefully.In addition, Wockhardt, based in Mumbai, is close to launching another innovative drug called Zaynich, which is undergoing Phase-3 trials after nearly 25 years of development. Describing it as groundbreaking, Dr. Habib Khorakiwala noted its administration to critically ill patients who were unresponsive to other antibiotics resulted in remarkable survival rates. Another promising antibiotic from Wockhardt, Nafithromycin, boasts a success rate of 97% and targets pneumonia, a significant achievement given the present 60% resistance rates to current treatments.Despite these advancements, there remains a significant challenge posed by a lack of focus on antibiotic development in major pharmaceutical industries, largely because of higher profitability in developing drugs for other conditions. A report by the Indian Council of Medical Research (ICMR) underscores this as it unveils emerging trends of resistance in prevalent pathogens like E. coli and Klebsiella pneumoniae, where effective treatments are dwindling.Healthcare experts advocate for urgent reforms in antibiotic prescription practices, emphasizing the need for employing narrow-spectrum antibiotics that precisely target bacterial infections without eradicating beneficial bacteria. Meanwhile, government agencies and partnerships, such as GARDP, are working to introduce newer antibiotics like zoliflodacin and cefiderocol in India in order to tackle rising resistance.As the battle against superbugs rages on, the commitment to responsible drug utilization and enhanced public health measures will determine the future effectiveness of these newly developed antibiotics. The situation is a potent reminder of the intertwined nature of society's health and the continuous fight against drug-resistant infections. Without cohesive action, common infections may soon regress to being untreatable.
